Companies news

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its stockholders approved the proposals to complete the proposed merger with TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) at its annual meeting of stockholders held on Monday, September 28, 2009. Concurrently, at the annual meeting of its stockholders, TorreyPines stockholders approved all of the proposals related to the merger with Raptor. The merger is expected to close after the satisfaction or waiver of all closing conditions specified in the merger agreement including customary regulatory approvals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

Details of the Proposed Raptor and TorreyPines Merger

On July 27, 2009, Raptor and TorreyPines entered into a definitive merger agreement. Immediately following completion of the merger, TorreyPines will change its name to "Raptor Pharmaceutical Corp." and common stock in the combined company will trade on The NASDAQ Capital Market under the symbol "RPTP." The merger of Raptor and TorreyPines would create a biopharmaceutical company with a pipeline of mid- to late-stage clinical development candidates and preclinical drug targeting platforms designed to improve drug delivery of existing therapeutics for orphan indications and underserved patient populations.

Under terms of the merger agreement, which were unanimously approved by the boards of directors of Raptor and TorreyPines, Raptor will be merged with and into a wholly-owned subsidiary of TorreyPines upon closing. TorreyPines will issue, and Raptor stockholders will receive, shares of TorreyPines common stock such that Raptor stockholders will own 95%, and TorreyPines stockholders will own 5%, of the combined company.

Additional Information About the Merger and Where to Find It

In connection with the merger, TorreyPines has filed a registration statement on Form S-4, which includes a joint proxy statement/prospectus, with the U.S. Securities Exchange Commission ("SEC"). Investors and security holders of Raptor and TorreyPines are urged to read the joint proxy statement/prospectus included in the registration statement filed on Form S-4 (including any amendments or supplements thereto) regarding the merger because it contains important information about Raptor and TorreyPines. Raptor's and TorreyPines' stockholders can obtain a copy of the joint proxy statement/prospectus, as well as other filings containing information about Raptor and TorreyPines, without charge, at the SEC's Internet website (www.sec.gov). Copies of the joint proxy statement/prospectus and Raptor's and TorreyPines' filings with the SEC can also be obtained, without charge, by directing a request to Raptor Pharmaceuticals Corp., 9 Commercial Blvd., Suite 200, Novato, CA 94949, Attention: Kim Tsuchimoto CFO, Fax No. +1-415-382-1368 or at the email address: ktsuchimoto@raptorpharma.com, with respect to Raptor, and by directing a request to TorreyPines Therapeutics, Inc., P.O. Box 231386, Encinitas, CA 92023-1386, Attention: Investor Relations or at the email address: cjohnson@tptxinc.com, with respect to TorreyPines.

In addition to the registration statement and related joint proxy statement/prospectus, each of Raptor and TorreyPines file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Raptor and/or TorreyPines at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at +1-800-SEC-0330 for further information on the public reference room. Raptor's and TorreyPines' filings, respectively, with the SEC are also available to the public from commercial document-retrieval services and at SEC's website at www.sec.gov, and from investor relations at Raptor and TorreyPines, respectively, at the addresses above.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Information regarding the directors and executive officers of Raptor and TorreyPines, respectively, is included, with respect to Raptor, in Raptor's Annual Report, as amended on Form 10-K/A for the year ended August 31, 2008 and Raptor's proxy statement for its 2008 Annual Meeting of Stockholders, which were filed with the SEC on December 23, 2008 and December 31, 2007, respectively, and with respect to TorreyPines, in TorreyPines' Annual Report on Form 10-K for the year ended December 31, 2008 and TorreyPines' proxy statement for its 2008 Annual Meeting of Stockholders, which were filed with the SEC March 27, 2009 and April 24, 2008 respectively. These documents are available free of charge at the SEC's web site at www.sec.gov and from investor relations at Raptor and TorreyPines, respectively, at the addresses above.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), and aldehyde dehydrogenase ("ALDH2") deficiency.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

About TorreyPines

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. TorreyPines' goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and chronic pain. TorreyPines currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is available at www.tptxinc.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statement: that the all closing conditions and regulatory approvals will be obtained to close the merger or that the merger will close at all; and that the combined company will list on the NASDAQ Capital Market or any national exchange. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Raptor's actual results to be materially different from these forward-looking statements. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in Raptor's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including the joint proxy statement/prospectus on Form S-4 filed by TorreyPines on August 19, 2009; Raptor's Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; Raptor's annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by that Form 10-K/A filed with the SEC on December 23, 2008; and Raptor's Form 10-Q filed with the SEC on July 15, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.

For more information, please contact: The Ruth Group Sara Ephraim Pellegrino (investors) / Janine McCargo (media) +1-646-536-7002 / +1-646-536-7033 spellegrino@theruthgroup.com / jmccargo@theruthgroup.com Kim Tsuchimoto, CFO +1-415-382-1390 ktsuchimoto@raptorpharma.com

Raptor Pharmaceuticals Corp.; TorreyPines Therapeutics

Sara Ephraim Pellegrino (investors), +1-646-536-7002, spellegrino@theruthgroup.com, or Janine McCargo (media), +1-646-536-7033, jmccargo@theruthgroup.com, both of The Ruth Group, or Kim Tsuchimoto, CFO of Raptor Pharmaceuticals Corp., +1-415-382-1390, ktsuchimoto@raptorpharma.com. Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO

Timberlake Energy Solutions Inc. purchases Blanchard Oil Field Lease

OVERLAND PARK, KS, Sept. 28 /PRNewswire-FirstCall/ -- Timberlake Energy Solutions Inc. - (T2YA.F) - in a continued effort to add to the corporations existing oil and gas operations has acquired the Blanchard Oil Field Lease. The 240 acre Kansas located oil field (producing) is undergoing a development program that the company expects will garner significant revenues from existing and additional production flow rates.

Timberlake CEO, Bob Bowersock also provided confirmation that the Burns Oil Lease is now up to full production. The company will make available production numbers once consistent flow rates are established expected by the end of October 2009.

Timberlake Energy Solutions management team and board of directors are committed to growing its business both organically and through accretive mergers and acquisitions.

http://www.timberlakeenergy.com/ About Timberlake Energy Solutions Inc.

Timberlake Energy Solutions Inc. is a junior exploration company focused on purchasing abandoned or under valued oil and gas leases in the United States. With an experienced technical team, these oil and gas wells are refurbished and outfitted with the latest in oil and gas recovery equipment. Timberlake Energy Solutions has advanced technology to reclaim and put these wells back into production, hence increasing the well value significantly. Timberlake operates exploration projects through joint ventures in the Appalachian Basin and owns interests in a number of petroleum and natural gas leases in Lambton, and Kent, Counties, Ontario. In addition to its main operating focus, the company is actively exploring projects in the Appalachian and Michigan Basins.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.

Timberlake Energy Solutions Inc.- (T2YA.F)

CONTACT: Bob Bowersock, President, Timberlake Energy Solutions Inc.,
(913) 449-9481, timberlake.ir@gmail.com

Sangamo BioSciences Announces Presentation at the JMP Securities Healthcare Conference

RICHMOND, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:30 am ET on Monday, October 5, 2009 at the Fourth Annual JMP Securities Healthcare Focus Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

Sangamo BioSciences, Inc.

CONTACT: Elizabeth Wolffe, Ph.D of Sangamo BioSciences, Inc.,
+1-510-970-6000, x271, ewolffe@sangamo.com

Web Site: http://www.sangamo.com/

Majesco Entertainment Company Mourns the Loss of Board Member Mark Stewart

EDISON, N.J., Sept. 28 /PRNewswire-FirstCall/ -- Majesco Entertainment Company (the "Company"), an innovative provider of video games for the mass market, is deeply saddened to announce that Mark Stewart passed away on September 21, 2009. Mr. Stewart served on Majesco's Board of Directors since January 17, 2007. He was a Member of the Audit Committee, the Nominating and Governance Committee, and the Compensation Committee.

Mr. Stewart worked as CEO, CFO, and held executive positions for many major corporations including, Kodak Polychrome Graphics, Eastman Kodak, Qualex, Paramount Communications, CBS, General Mills, and PepsiCo. In addition to Majesco, he recently held directorships at Blue Man Productions and The Maritime Aquarium in Norwalk, CT.

"Mark was an active and valued member of Majesco's Board of Directors and his vision, contributions, and good spirit will be missed. On behalf of Majesco, I would like to extend our sympathies to the entire Stewart family. He was an inspiration to all of us and we are saddened by his passing," said Allan Grafman, Chairman of the Board of Majesco Entertainment.

"Majesco has lost a great friend and advisor. We were truly fortunate to have been able to draw on Mark's wisdom, business experience and insight. Mark will be deeply missed by those of us who were fortunate enough to know him. We wish to extend our deepest condolences to Mark's family," said Jesse Sutton, Chief Executive Officer of Majesco.

About Majesco Entertainment Company

Majesco Entertainment Company is a provider of video games for the mass market. Building on more than 20 years of operating history, the company is focused on developing and publishing a wide range of casual and family oriented video games on leading console and portable systems. Product highlights include Cooking Mama(TM) and Cake Mania®2 for Nintendo DS(TM), and Cooking Mama World Kitchen and Jillian Michaels' Fitness Ultimatum 2009 for Wii(TM). The company's shares are traded on the Nasdaq Stock Market under the symbol: COOL. Majesco is headquartered in Edison, NJ and has an international office in Bristol, UK. More information about Majesco can be found online at http://www.majescoentertainment.com/. @Majesco is on twitter or at http://www.twitter.com/majesco.

Majesco Entertainment Company

CONTACT: John Gross, Chief Financial Officer, Majesco Entertainment
Company, +1-732-225-8910; or Mike Smargiassi or Denise Roche, Brainerd
Communicators, Inc., +1-212-986-6667

Web Site: http://www.majescoentertainment.com/

Raptor Pharmaceuticals and TorreyPines Therapeutics Receive Stockholder Approvals to MergeMerger to Create NASDAQ-Listed Biopharmaceutical Company named Raptor Pharmaceutical Corp.

NOVATO, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (BULLETIN BOARD: RPTP) , today announced that its stockholders approved the proposals to complete the proposed merger with TorreyPines Therapeutics, Inc. ("TorreyPines") at its annual meeting of stockholders held on Monday, September 28, 2009. Concurrently, at the annual meeting of its stockholders, TorreyPines stockholders approved all of the proposals related to the merger with Raptor. The merger is expected to close after the satisfaction or waiver of all closing conditions specified in the merger agreement including customary regulatory approvals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO ) Details of the Proposed Raptor and TorreyPines Merger

Additional Information About the Merger and Where to Find It

In connection with the merger, TorreyPines has filed a registration statement on Form S-4, which includes a joint proxy statement/prospectus, with the U.S. Securities Exchange Commission ("SEC"). Investors and security holders of Raptor and TorreyPines are urged to read the joint proxy statement/prospectus included in the registration statement filed on Form S-4 (including any amendments or supplements thereto) regarding the merger because it contains important information about Raptor and TorreyPines. Raptor's and TorreyPines' stockholders can obtain a copy of the joint proxy statement/prospectus, as well as other filings containing information about Raptor and TorreyPines, without charge, at the SEC's Internet website (http://www.sec.gov/). Copies of the joint proxy statement/prospectus and Raptor's and TorreyPines' filings with the SEC can also be obtained, without charge, by directing a request to Raptor Pharmaceuticals Corp., 9 Commercial Blvd., Suite 200, Novato, CA 94949, Attention: Kim Tsuchimoto CFO, Fax No. 415-382-1368 or at the email address: ktsuchimoto@raptorpharma.com, with respect to Raptor, and by directing a request to TorreyPines Therapeutics, Inc., P.O. Box 231386, Encinitas, CA 92023-1386, Attention: Investor Relations or at the email address: cjohnson@tptxinc.com, with respect to TorreyPines.

In addition to the registration statement and related joint proxy statement/prospectus, each of Raptor and TorreyPines file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Raptor and/or TorreyPines at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Raptor's and TorreyPines' filings, respectively, with the SEC are also available to the public from commercial document-retrieval services and at SEC's website at http://www.sec.gov/, and from investor relations at Raptor and TorreyPines, respectively, at the addresses above.

Information regarding the directors and executive officers of Raptor and TorreyPines, respectively, is included, with respect to Raptor, in Raptor's Annual Report, as amended on Form 10-K/A for the year ended August 31, 2008 and Raptor's proxy statement for its 2008 Annual Meeting of Stockholders, which were filed with the SEC on December 23, 2008 and December 31, 2007, respectively, and with respect to TorreyPines, in TorreyPines' Annual Report on Form 10-K for the year ended December 31, 2008 and TorreyPines' proxy statement for its 2008 Annual Meeting of Stockholders, which were filed with the SEC March 27, 2009 and April 24, 2008 respectively. These documents are available free of charge at the SEC's web site at http://www.sec.gov/ and from investor relations at Raptor and TorreyPines, respectively, at the addresses above.

About Raptor Pharmaceuticals Corp.

For additional information, please visit http://www.raptorpharma.com/. About TorreyPines

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statement: that the all closing conditions and regulatory approvals will be obtained to close the merger or that the merger will close at all; and that the combined company will list on the NASDAQ Capital Market or any national exchange. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Raptor's actual results to be materially different from these forward-looking statements. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in Raptor's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including the joint proxy statement/prospectus on Form S-4 filed by TorreyPines on August 19, 2009; Raptor's Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; Raptor's annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by that Form 10-K/A filed with the SEC on December 23, 2008; and Raptor's Form 10-Q filed with the SEC on July 15, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov/. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.

For more information, please contact: The Ruth Group Sara Ephraim Pellegrino (investors) / Janine McCargo (media) (646) 536-7002 / (646) 536-7033 spellegrino@theruthgroup.com / jmccargo@theruthgroup.com Kim Tsuchimoto, CFO 415-382-1390 ktsuchimoto@raptorpharma.com

Photo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com Raptor Pharmaceuticals Corp.; TorreyPines Therapeutics

CONTACT: Sara Ephraim Pellegrino (investors), +1-646-536-7002,
spellegrino@theruthgroup.com, or Janine McCargo (media), +1-646-536-7033,
jmccargo@theruthgroup.com, both of The Ruth Group, or Kim Tsuchimoto, CFO of
Raptor Pharmaceuticals Corp., +1-415-382-1390, ktsuchimoto@raptorpharma.com

Web Site: http://www.raptorpharma.com/

Idenix Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference

CAMBRIDGE, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. announced today that management will present a corporate overview at the upcoming JMP Securities Healthcare Focus Conference on Monday, October 5, 2009 at 8:30 a.m. ET at The New York Palace Hotel.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com/. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com/.

Idenix Pharmaceuticals Contact:

Teri Dahlman (617) 995-9905

Idenix Pharmaceuticals, Inc.

CONTACT: Teri Dahlman, +1-617-995-9905

Web Site: http://www.idenix.com/

Anadys Pharmaceuticals to present at the JMP Securities Healthcare Focus Conference

SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Monday, October 5, 2009 at 11:00 a.m. EDT (8:00 a.m. PDT). The conference is being held at The New York Palace Hotel. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys, including an update on the non-clinical development status of the ANA598 program.

The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com/. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through October 19, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended June 30, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Anadys Pharmaceuticals, Inc.

CONTACT: Investors, Amy Conrad of Anadys Pharmaceuticals, Inc.,
+1-858-530-3607, aconrad@anadyspharma.com; or Media, Ian Stone,
ian.stone@russopartnersllc.com, or David Schull,
david.schull@russopartnersllc.com, both of Russo Partners, LLC,
+1-619-528-2220, for Anadys Pharmaceuticals, Inc.

Web Site: http://www.anadyspharma.com/

EQ Labs Smart Energy Drink Complements the Energy Drink Industry

LAS VEGAS, Sept. 28 /PRNewswire-FirstCall/ -- When deciding to make Las Vegas, Nevada its headquarters, EQ Labs, Inc. (Pink Sheets: EQLB) didn't consider other energy drink manufacturers to constitute a threat, nor did the Company consider itself a threat to the multitude of companies already in existence. Instead, the Company's opinion was that its EQ Smart Energy Drink effervescent tablets would complement the energy drink industry. Consumers would have a new, safe, and healthy energy supplement compared to competing energy drinks, which are loaded with caffeine, calories, carbohydrates, and all very similar in taste.

Given the abundance of energy drink manufacturers in the Las Vegas Valley, the Company embraced the belief, "If we can succeed here, we can succeed anywhere." The Company recognized the significance of entering into agreements with national distributors and retail chains as a means of selling into these large volume consumer markets, but believed it unwise to overlook opportunities in its own backyard and started working closely with smaller local distributors and retail establishments.

"This strategy, while simplistic, is paying off tremendously," stated Mike Villa, the Company's Sales Manager. "Yes, we've been fortunate enough to enter into agreements with large, national distributors like McLane Distributors Co., who service thousands of 7 - Eleven (corporate-owned convenience stores), but our goal to place our product in the hundreds of 7 - Eleven franchise stores in the Las Vegas area has also been realized. It entailed calling on local merchants and demonstrating the added value of stocking our products -- selling them on the fact that EQ Smart Energy Drink tablets will complement and increase their energy drink sales."

"In essence, they could receive a substantial mark-up margin by offering an energy drink product for less than $1.00 per unit," he added. "As a result of securing sales agreements with local distributors like FoodPro and increasing the number of accounts with retail outlets throughout the region, we were able to hire and train additional sales staff to systematically introduce the product throughout the region," Villa went on to state.

"This is good news," stated Bob Fain, the COO of EQ Labs, Inc. "It demonstrates the commercial success of our product on a local basis, which has opened doors to other domestic markets. When we embarked on this strategy, our belief was that it didn't make sense to overlook the multitude of smaller distribution opportunities right here in our backyard, while chasing after larger companies outside of our own geographic region. We believe our successes complemented the energy drink industry by providing viable alternatives for local consumers. Given the millions of visitors to Las Vegas, our strong presence here also serves as a gateway to additional accounts on a national and international basis, and we look forward to embracing them," Fain continued. "We're now seeing inquiries from other significant domestic distributors, and plan on formally announcing the consummation of contracts with two of the nation's leading retail chains in the very near future."

About EQ Labs, Inc.: EQ Smart Energy Drink® is an effervescent tablet that provides instant energy in any beverage. Consisting of a blend of essential vitamins, Gingko Biloba, and less caffeine than a cup of coffee, EQ keeps you going any time -- day or night. One tablet of EQ Smart Energy Drink® is the equivalent of one can of any competing energy drink on the market, yet it's more economically efficient and convenient for consumer to use than most energy drink products in the marketplace. The product does not have to be kept cold to enjoy nor does it require a lot of space. EQ is all about natural energy and living the modern lifestyle.

The Company presently distributes its products through national distributors, such as McLane Distributors, which distributes to the national convenience store chain, 7 - Eleven, and numerous other regional distributors, and has been approved for consumer consumption by the Ministries of Health in Latin American countries such as Mexico and Brazil. For more information about EQ Labs, visit http://www.drinkeq.com/.

Safe Harbor Statement: Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. The forward-looking statements are subject to risks and uncertainties including, without limitation, changes in levels of competition, possible loss of customers, and the company's ability to attract and retain key personnel.

Contact: Maurice "Mo" Owens, CEO EQ Labs, Inc. TEL: 702-445-7762 mo@drinkeq.com; or Bob Fain, COO bob@drinkeq.com http://www.drinkeq.com/ http://www.myspace.com/eq4u

EQ Labs, Inc.

CONTACT: Maurice "Mo" Owens, CEO, +1-702-445-7762, mo@drinkeq.com; or
Bob Fain, COO, bob@drinkeq.com, both of EQ Labs, Inc.

Web Site: http://www.drinkeq.com/

ONEOK Partners Nearing Completion of Fargo Lateral Expansion

TULSA, Okla., Sept. 28 /PRNewswire-FirstCall/ -- ONEOK Partners, L.P. announced today that its subsidiary, Viking Gas Transmission Company, is nearing completion of a $14.7 million expansion of the Fargo lateral segment of its natural gas pipeline.

Approximately 10 miles of the 18-mile pipeline will be expanded by replacing the existing eight-inch pipe with 12-inch pipe, which will increase the pipeline's throughput capacity to 91 million cubic feet per day (MMcf/d) from 53 MMcf/d. Northern States Power, a subsidiary of Xcel Energy, is the largest volume shipper on the lateral.

"The increased demand experienced during the last few heating seasons made this a necessary and important project for the region," said Terry K. Spencer, ONEOK Partners chief operating officer. "The expansion of the Fargo lateral is another example of ONEOK Partners' strategic commitment to providing asset solutions to meet the growing energy needs in the marketplace."

The expansion is expected to be complete by mid-October of this year. Once complete, the facility will transport increased volumes of natural gas to Northern States Power delivery points in Fargo, N.D., and Dilworth and Moorhead, Minn.

View map showing expansion.

ONEOK Partners, L.P. is one of the largest publicly traded master limited partnerships and is a leader in the gathering, processing, storage and transportation of natural gas in the U.S. and owns one of the nation's premier natural gas liquids (NGL) systems, connecting NGL supply in the Mid-Continent and Rocky Mountain regions with key market centers. Its general partner is a wholly owned subsidiary of ONEOK, Inc. , a diversified energy company, which owns 45.1 percent of the partnership. ONEOK is one of the largest natural gas distributors in the United States, and its energy services operation focuses primarily on marketing natural gas and related services throughout the U.S.

For more information, visit the Web site at http://www.oneokpartners.com/.

Some of the statements contained and incorporated in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements relate to financial adjustments in connection with the accelerated share repurchase program and other matters. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements in certain circumstances.

Analyst Contact: Andrew Ziola 918-588-7163 Media Contact: Brad Borror 918-588-7582 OKS-FD

ONEOK Partners, L.P.

CONTACT: Analysts, Andrew Ziola, +1-918-588-7163, or Media, Brad Borror,
+1-918-588-7582, both for ONEOK Partners, L.P.

Web Site: http://www.oneokpartners.com/

Patriot Coal CEO to Speak at Johnson Rice Energy Conference

ST. LOUIS, Sept. 28 /PRNewswire-FirstCall/ -- Patriot Coal Corporation today announced that its Chief Executive Officer, Richard M. Whiting, will speak at the Johnson Rice Energy Conference on Wednesday, October 7 at 3:15 p.m. Central Daylight Time at the Ritz Carlton Hotel in New Orleans.

About Patriot Coal

Patriot Coal Corporation is a leading producer and marketer of coal in the eastern United States, with 14 current mining complexes in Appalachia and the Illinois Basin. The Company ships to domestic and international electric utilities, industrial users and metallurgical coal customers, and controls approximately 1.8 billion tons of proven and probable coal reserves. The Company's common stock trades on the New York Stock Exchange under the symbol PCX.

Patriot Coal Corporation

CONTACT: Janine Orf of Patriot Coal Corporation, +1-314-275-3680,
jorf@patriotcoal.com

Web Site: http://www.patriotcoal.com/

SEQUENOM Announces Completion of Independent InvestigationSEQUENOM to Hold Conference Call Today at 2:00 p.m. Pacific Time

SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. today announced the completion of the independent investigation by a special committee of independent directors related to the test data and results for the company's noninvasive prenatal test for Trisomy 21 (Down syndrome). The independent counsel engaged by the special committee interviewed over 40 witnesses and reviewed over 300,000 documents and emails.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

Based on the special committee's work and recommendations, the independent members of the company's board of directors have concluded that as a result of the company's attempted transition from researching potential molecular diagnostic tests to developing and commercializing those tests, the company failed to put in place adequate protocols and controls for the conduct of studies in the Trisomy 21 program at the company. Certain of the company's employees also failed to provide adequate supervision. In the absence of such protocols, controls and supervision, the test data and results in the company's Trisomy 21 program included inadequately substantiated claims, inconsistencies and errors. Due to deficiencies in the company's disclosure controls and procedures, in a number of instances such test data and results were reported to the public in the company's press releases and other public statements.

At the recommendation of the special committee, the company's board of directors has begun implementing a number of remedial measures, including:

-- new disclosure controls and procedures; -- changes in the company's organizational and reporting structure; -- enhanced training in ethics and scientific processes for the company's employees; -- new procedures for the conduct of research and development and clinical studies, including increased roles and responsibilities for independent third parties; -- new procedures for the storage and management of samples for testing; and -- creation of a science committee of the company's board of directors to oversee its research and development strategy and activities.

The company has terminated the employment of its president and chief executive officer, Harry Stylli, Ph.D., and its senior vice president of research and development, Elizabeth Dragon, Ph.D., effective immediately. In connection with the termination of Dr. Stylli's employment, the company's board of directors has requested that he resign as a director, which he is obligated to do under the terms of his employment agreement. The company has obtained the resignation of its chief financial officer, Paul Hawran, and one other officer. The company also terminated the employment of three other employees. While each of these officers and employees has denied wrongdoing, the special committee's investigation has raised serious concerns, resulting in a loss of confidence by the independent members of the company's board of directors in the personnel involved.

Members of the special committee and its independent counsel will make a presentation on the investigation to the staff of the Securities and Exchange Commission.

Effective today, the company's board of directors has appointed chairman of the board Harry F. Hixson, Jr., Ph.D., former president and chief operating officer of Amgen, Inc., and director Ronald M. Lindsay, Ph.D., to serve on an interim basis as chief executive officer and senior vice president of research and development, respectively. The company's board of directors has also designated controller Justin J. File as principal financial and accounting officer.

The company reiterates that it is no longer relying on, and the public should no longer rely on, any of the previously announced test data and results for the company's noninvasive prenatal test for Trisomy 21.

At this time the company is unable to provide guidance on the timetable for the completion of research and development or for the potential commercialization of its Trisomy 21 test. However, the company continues to believe in the science underlying the test and is continuing its research and development program for this test. The release of fetal material into maternal circulation has been validated by a number of academic laboratories and potential competitors as well as the company. Sequenom continues to believe that this fetal material, including nucleic acids, will provide important information about the genetic makeup of the fetus and that this information may become the basis for new diagnostic tests. As a pioneer in this area, Sequenom intends to pursue these important developments that may have a major impact on maternal and fetal health.

Conference Call Information

The company has scheduled a conference call for 2:00 p.m. Pacific time today to discuss this announcement.

Domestic callers: 1-800-299-0433 International callers: +1-617-801-9712 Passcode: 56566438 Webcast information: Visit http://ir.sequenom.com/.

The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at http://www.earnings.com/, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (http://www.streetevents.com/).

A webcast replay will be available on the SEQUENOM Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-888-286-8010 for domestic callers, or +1-617-801-6888 for international callers, and entering reservation code 12857429.

About SEQUENOM

Sequenom, Inc. is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com/ to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM® is a trademark of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the implementation of remedial measures, the company's plans to develop a noninvasive prenatal test for Trisomy 21 and the science underlying such a test, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the company's ability to develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal diagnostics and laboratory developed tests, the company's ability to attract and retain personnel, reliance upon the collaborative efforts of other parties, the company's ability to successfully implement the remedial measures recommended by the special committee and the effectiveness of those measures, the company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals and other risks detailed from time to time in the company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Photo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com SEQUENOM, Inc.

CONTACT: Ian Clements, Ph.D., Sr. Director, Corp. Communications of
SEQUENOM, Inc., +1-858-202-9000; or Investor Relations, Jody Cain of
Lippert/Heilshorn & Associates, +1-310-691-7100, jcain@lhai.com; or Media
Relations, Dan Budwick of Pure Communications, +1-973-271-6085, both for
SEQUENOM, Inc.

Web Site: http://www.sequenom.com/

Company News On-Call: http://www.prnewswire.com/comp/124192.html

AMB Property Corporation(R) to Participate in the Bank of America Merrill Lynch Global Real Estate Conference

SAN FRANCISCO, Sept. 28 /PRNewswire-FirstCall/ -- AMB Property Corporation® , a leading global owner, operator and developer of industrial real estate, today announced that Guy F. Jaquier, the company's president, Europe & Asia, is scheduled to make an appearance at the Bank of America Merrill Lynch Global Real Estate Conference, which is being held at the Westin Times Square in New York City.

Jaquier will participate on the "Global Industrial Property Investment and Development" panel. This session will take place on Wednesday, September 30, 2009, at 2:10 PM EDT / 11:10 AM PDT.

The panel session will be available afterward via audio-webcast and can be accessed in the Investor Relations section of the company's website at http://www.amb.com/. The webcast replay will be available until 8:00 PM EDT / 5:00 PM PDT Wednesday, October 14, 2009.

AMB Property Corporation.® Local partner to global trade.(TM)

AMB Property Corporation® is a leading owner, operator and developer of industrial real estate, focused on major hub and gateway distribution markets in the Americas, Europe and Asia. As of June 30, 2009, AMB owned, or had investments in, on a consolidated basis or through unconsolidated joint ventures, properties and development projects expected to total approximately 156.9 million square feet (14.6 million square meters) in 48 markets within 14 countries. AMB invests in properties located predominantly in the infill submarkets of its targeted markets. The company's portfolio is comprised of High Throughput Distribution® facilities--industrial properties built for speed and located near airports, seaports and ground transportation systems.

AMB's press releases are available on the company website at http://www.amb.com/ or by contacting the Investor Relations department at +1 415 394 9000.

AMB Property Corporation

CONTACT: Tracy A. Ward, Vice President, IR & Corporate Communications,
+1-415-733-9565, tward@amb.com, or Rachel E. M. Bennett, Director, Media &
Public Relations, +1-415-733-9532, rbennett@amb.com, both of AMB Property
Corporation

Web Site: http://www.amb.com/

China Pharma Holdings, Inc. Announces Approval for NYSE Amex Listing

HAIKOU CITY, China, Sept. 28 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (BULLETIN BOARD: CPHI) , which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has received approval to list its securities on NYSE Amex.

China Pharma expects to begin trading on NYSE Amex on Wednesday, September 30, 2009. In connection with its listing on NYSE Amex, the Company's ticker symbol will change to "CPHI" from "CPHI.OB."

Ms. Zhilin Li, CEO and President of China Pharma, commented, "It is a major milestone to move to NYSE Amex, and we are proud of our fulfillment of this target. We believe that NYSE Amex provides excellent exposure for companies from emerging markets, such as ours. This step underscores our commitment to generating long-term value for our shareholders."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com/ .

Safe Harbor Statement

Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact: China Pharma Holdings, Inc. Tel: +86-898-6681-1730 Email: hps@chinapharmaholdings.com ICR, Inc. Christine Duan Tel: +1-203-682-8200

China Pharma Holdings, Inc.

CONTACT: China Pharma Holdings, Inc., +86-898-6681-1730,
hps@chinapharmaholdings.com; or Christine Duan of ICR, Inc., +1-203-682-8200

Web site: http://www.chinapharmaholdings.com/

VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ

SAN FRANCISCO, Sept. 28 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. , a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on September 23, 2009, it received a deficiency letter from The NASDAQ Stock Market notifying the Company of its failure to regain compliance with the board independence requirements, as set forth in Listing Rules 5605(b)(1) and 5605(c)(2)(A), respectively (the "Independence Rules"), and that the Company's securities are, therefore, subject to delisting from The NASDAQ Capital Market. The Company had previously announced that due to the passing of Richard L. Anderson, who served as an independent director on the Company's Board of Directors and as a member of the Audit Committee, Compensation Committee and Nominating and Governance Committee, the Company no longer complied with the Independence Rules. The Company was given until September 17, 2009 to regain compliance with these requirements. The Company will present its written views with respect to this deficiency to the NASDAQ Listing Qualifications Panel (the "Panel") by September 30, 2009.

The Company has had a hearing with the Panel and presented its plan of compliance with respect to its failure to satisfy the Independence Rules, as well as its plan to satisfy NASDAQ's minimum $2.5 million stockholders' equity and $1.00 minimum bid price requirements for continued listing. The Company is awaiting a decision from the Panel. There can be no assurance that the Company will be able to achieve or sustain the requirements under the NASDAQ Listing Rules to insure that it will maintain its NASDAQ listing.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com/.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- the results of our hearing with the NASDAQ Listing Qualifications Panel and our ability to comply with the NASDAQ rules for continued listing; -- our ability to borrow additional amounts under the loan from Bay City Capital, which is subject to the discretion of Bay City Capital; -- our ability to obtain necessary financing in the near term, including amounts necessary to repay the loan from Bay City Capital by the October 31, 2009 maturity date (or earlier if certain repayment acceleration provisions are triggered); -- our ability to control our operating expenses; -- our ability to comply with covenants included in the loan from Bay City Capital; -- our ability to maintain the listing of our common stock on NASDAQ; -- our ability to timely recruit and enroll patients in any future clinical trials; -- our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA- 2291, thereby impairing the validity or statistical significance of our clinical trials; -- our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials; -- complexities in designing and implementing cardiometabolic clinical trials using surrogate endpoints in Phase 1 and Phase 2 clinical trials which may differ from the ultimate endpoints required for registration of a candidate drug; -- the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- if the results of the ACS and CEA studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials; -- our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291; -- our ability to successfully commercialize VIA-2291; -- our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development; -- our ability to obtain and protect our intellectual property related to our product candidates; -- our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche; -- our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291; -- our ability to form and maintain collaborative relationships to develop and commercialize our product candidates; -- general economic and business conditions; and -- the other risks described under Item 1A "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as supplemented by the risks described under Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009 and June 30, 2009, each on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

VIA Pharmaceuticals, Inc.

CONTACT: James G. Stewart, Senior Vice President and Chief Financial
Officer of VIA Pharmaceuticals, Inc., +1-415-283-2204

Web Site: http://www.viapharmaceuticals.com/

Onyx Pharmaceuticals Initiates Phase 1 Study of ONX 0801 in Advanced Solid Tumors

EMERYVILLE, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it has begun enrolling patients in a Phase 1 study of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase (TS) inhibitor, as a potential treatment for advanced solid tumors. This open-label, dose-finding study will evaluate the safety and pharmacokinetics of ONX 0801 in patients with advanced solid tumors.

"We are pleased to advance this product candidate so quickly into the clinic, following our acquisition of the compound late last year. ONX 0801 has a high selectivity for cancer cells that we believe will distinguish it from other agents in this proven class of drugs," said Tony Coles, M.D., president and chief executive officer of Onyx. "We expect this forward momentum in building our portfolio to continue, as we strategically maximize opportunities that will drive long-term sustainable growth."

Trial Design

The open-label, dose-finding Phase 1 study is evaluating the safety and pharmacokinetics of ONX 0801 in approximately 60 cancer patients with advanced solid tumors. Cohorts of 3 to 6 patients will receive ONX 0801 at escalating doses until a maximum tolerated dose is determined. Each patient will receive a 3-hour intravenous infusion of ONX 0801 weekly (i.e., on days 1, 8, and 15) of repeated 21-day treatment cycles.

About ONX 0801

ONX 0801 is designed to work by combining two proven approaches to improving outcomes for cancer patients. These include receptor-mediated targeting of tumor cells and inhibition of thymidylate synthase (TS), a key enzyme involved in cell growth and division. In pre-clinical studies, ONX 0801 targeted malignant cells that overexpress the alpha-folate receptor, which is located on the cell's surface. ONX 0801 is distinct from currently marketed TS inhibitors due to its selective tumor cell-specific uptake by the alpha-folate receptor, which is overexpressed in a number of tumor types with significant unmet needs, including ovarian cancer, lung cancer, breast cancer, and colorectal cancer. ONX 0801 was discovered at the Institute for Cancer Research in the UK and is licensed to Onyx by BTG International.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com/.

Forward-Looking Statements

This news release may contain "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding timing, progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of ONX 0801. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc.

CONTACT: Investors, Julie Wood, Vice President, Investor Relations,
+1-510-597-6505, or Media, Lori Murray, Associate Director, Corporate
Communications, +1-510-597-6394, both of Onyx Pharmaceuticals, Inc.

Web Site: http://www.onyx-pharm.com/

Berliner Communications Announces Fourth Quarter and Full-Year 2009 Financial Results

ELMWOOD PARK, N.J., Sept. 28 /PRNewswire-FirstCall/ -- Berliner Communications, Inc. ("BCI" or the "Company") (BULLETIN BOARD: BERL) , a leading provider of infrastructure services to the telecommunications industry, today announced financial results for the fiscal fourth quarter and full-year ending June 30, 2009.

Business and Financial Highlights -- Awarded multi-million dollar project to provide in-building cellular communications to major U.S. international airport; -- Awarded new contracts with Cox Communications and other national cable multiple system operators, or MSOs; -- Launched 4G WiMAX site acquisition, zoning and/or construction projects in 11 markets across the U.S.; -- Launched LTE, or Long Term Evolution, project in Northern California market; -- Awarded Company's first international tower build project in Dubai; -- Opening new 76,000 square foot headquarters in Fairlawn, NJ; and expanded national footprint with new offices in Chicago, Illinois and additional presence in North Boston, Massachusetts, San Antonio and Austin, Texas and San Francisco Bay area in California; -- Backlog increased by 175% from $9.7 million on December 31, 2008 to $26.7 million on August 31, 2009.

Rich Berliner, CEO of BCI, stated, "Fiscal 2009 was a challenging year for BCI, as it was for many companies during these difficult economic times. It was a year of transition for us and our industry. As I noted last quarter, some of our major customers are in the process of building new networks, including 4G, WiMAX, and LTE based networks. As our customers began to ramp up these major projects during the year, we maintained a strong and growing platform to support these large-scale projects, but these ramp-ups have taken much longer than expected. These delays had a significant negative impact on our revenue and profitability for the year. Nevertheless, I firmly believe our strategy of continuing to maintain a strong platform to support future growth is the right long-term decision for our company. While many other companies cut their resources to the bone in the face of this uncertainty, we seized the opportunity to organically grow our resources and geographic reach, including new offices in Chicago and additional satellite offices in North Boston, Massachusetts, San Antonio and Austin, Texas and the San Francisco Bay area to supplement our existing presence in these regions. Now we are strongly positioned to take advantage of the large-scale growth opportunities we see in the industry in fiscal 2010 and beyond."

"We have recently signed national agreements with some of the largest cable, fiber and wireless companies in the country," Mr. Berliner continued. "I am pleased to announce a multi-million dollar in-building project at a major U.S. international airport. We have also dramatically expanded our work on 4G around the country, with significant site acquisition work in house and new construction starting in several markets. Our backlog of work continues to increase, from $9.7 million on December 31, 2008 to $26.7 million on August 31, 2009. We believe this backlog number is an important indicator of our increasing customer demand and revenue growth track."

"While I am disappointed with our financial results, I am extremely proud of our recent contract wins, and I believe fiscal 2010 will be a positive year for BCI, and we fully expect year over year revenue growth. This expectation is highlighted by several leading indicators that we are seeing, including our recent contract wins, our growing backlog, and the ever increasing need for robust telecom infrastructure. Ongoing customer conversations are indicating that the rapid growth in wireless network usage, especially with the proliferation of wireless data applications, is outpacing the existing infrastructure in the U.S., putting pressure on wireless carriers and other operators to increase spending on improving existing networks, and building new networks."

"During the past year, we made the strategic decision to diversify and move to become a full service telecom infrastructure services provider, rather than remain exclusively wireless-focused. We see the convergence of communications networks continuing in fiscal 2010 and beyond, and to that end we are now servicing customers in the cable, wire-line and fiber space, in addition to our traditional wireless customers. As the needs of these customers overlap, we see an opportunity to be uniquely positioned to service these complex needs. We also continue to win work for government projects, particularly in the public safety communications area, and we expect this part of our business to continue to grow. We have invested in building a national business development team, led by a former cable industry executive. This team has helped us grow our customer base, which now includes a prestigious roster of Fortune 1000 companies. We have more customers, in more industries, and in more markets, than ever before in the history of company."

Fiscal Fourth-Quarter 2009 Financial Results

For the fiscal fourth quarter ended June 30, 2009, total revenue decreased 35% to $15.8 million from $24.4 million for the quarter ended June 30, 2008. This decrease is primarily due to decreased revenue in the site acquisition and zoning segment and delays by our customers in starting major new construction projects.

Total operating expenses for the quarter ended June 30, 2009 decreased 28% to $4.8 million from $6.7 million for the quarter ended June 30, 2008. This decrease was primarily due to decreases in payroll, bad debt, insurance, and travel and entertainment expenses.

Our fiscal fourth-quarter 2008 income from operations of $5.2 million decreased to a loss from operations of $(1.0) million in fiscal fourth-quarter 2009. Net income (loss) allocable to common shareholders decreased to $(0.7) million, or $(0.02) per basic and fully diluted weighted average shares outstanding (based on 26.5 million basic and fully diluted weighted average shares outstanding) for the quarter ended June 30, 2009, from $2.2 million, or $0.11 per basic and $0.08 per fully diluted weighted average shares outstanding (based on 20.1 million and 27.1 million weighted average shares outstanding, respectively) for the quarter ended June 30, 2008.

Fiscal Full-Year 2009 Financial Results

Total revenues decreased 58% to $54.5 million for the year ended June 30, 2009 from $128.4 million for the year ended June 30, 2008. This decrease is primarily due to significant delays in our customers' projects in the infrastructure construction and technical services segment.

Gross profit for the year ended June 30, 2009 was $15.7 million, or 29% gross profit margin, compared to $44.9 million, or 35% gross profit margin, for the year ended June 30, 2008. This decrease in gross margin was in part caused by a change in revenue mix due to an increase in infrastructure construction and technical services revenue, from 77% of total revenue to 82%. Margins from infrastructure construction and technical services are typically lower than those associated with site acquisition and zoning.

Total operating expenses for the year ended June 30, 2009 decreased 20% to $20.5 million from $25.7 million for the year ended June 30, 2008. Income from operations decreased to a loss of $6.0 million from $18.0 million for the year-ago period. Net income (loss) allocable to common shareholders decreased to $(3.4) million, or $(0.13) per basic and fully diluted weighted average shares outstanding (based on 26.4 million weighted average shares outstanding) from $8.5 million or $0.47 per basic and $0.31 per fully diluted weighted average shares outstanding (based on 17.9 million and 27.2 million weighted average shares outstanding, respectively) for the year ended June 30, 2008.

EBITDA*, that is operating income (loss) plus the (gain) loss on sale of fixed assets, plus depreciation expense, decreased from $19.2 million to $(4.8) million, in fiscal 2009 compared to the prior year. A reconciliation of EBITDA to income from operations is as follows:

(Amounts in Thousands) (Unaudited) Three Months Ended Year Ended June 30, 2009 2008 2009 2008 ------- ------- ------- ------- Income from Operations $(1,003) $5,187 $(6,045) $18,038 Depreciation and Amortization Expense 334 349 1,285 1,190 (Gain) loss on sale of fixed assets 1 (19) (8) (11) ------- ------- ------- ------- EBITDA $(668) $5,517 $(4,768) $19,217 ======= ======= ======= =======

At June 30, 2009, the Company had cash and cash equivalents of approximately $1.4 million and net working capital of approximately $14.3 million. Shareholders' equity decreased 1% to $22.0 million from $22.3 million at June 30, 2008.

Mr. Berliner continued, "As I have noted in the past, we anticipated some lumpiness in our financial performance, and that expectation was proven out in fiscal 2009. We believe we are entering an upswing in our business cycle, and we have the contracts and backlog to support that assertion. The wireless sector of the telecom industry is growing exponentially, and subscriber usage is driving the need to upgrade existing networks and develop and install new communications networks to serve these needs. BCI is positioned to ride this wave of growth, and we are extremely optimistic about the opportunities we see in fiscal 2010 and beyond."

Conference Call:

Management will be hosting a conference call to review the quarterly results at 4:30 PM, today, Monday, September 28, 2009. Interested parties may access the call by calling 877-941-8416 from within the United States, or 480-629-9808 if calling internationally, approximately five minutes prior to the start of the call. A replay will be available through October 12, 2009 and can be accessed by dialing 800-406-7325 (U.S.), 303-590-3030 (Int'l), passcode 4161336.

This call is being web cast by ViaVid Broadcasting and can be accessed at http://www.bcisites.com/ or at ViaVid's website at http://www.viavid.net/ or by going to the following link http://viavid.net/dce.aspx?sid=00006A75. The web cast can be accessed until October 12, 2009. To access the web cast, you will need to have the Windows Media Player on your desktop. For the free download of the Media Player please visit: http://www.microsoft.com/windows/windowsmedia/en/download.

About Berliner Communications, Inc.

Berliner Communications, Inc. and its wholly owned operating subsidiary, BCI Communications, Inc., are headquartered in Elmwood Park, New Jersey. BCI is an end-to-end provider of outsourced services for the wireless communications industry, including planning, deployment and management of network build-outs. BCI provides wireless carriers with comprehensive real estate site acquisition and zoning services, radio frequency and network design and engineering, infrastructure equipment construction and installation, radio transmission base station modification and project management services. For more information about Berliner's services, please visit http://www.bcisites.com/.

The statements in this press release, which are not historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, without limitation, risks detailed in our filings with the United States Securities and Exchange Commission, the risk that future trends we have identified, including, but not limited to our stock price, trading volume, top and bottom-line growth and liquidity, do not materialize or if they materialize that they do not have the beneficial effect we anticipate, as well as the risk that we will not be able to achieve our sales and profitability goals. All forward-looking statements in this document are made as of the date hereof, based on information available to us on the date hereof, and we disclaim any intention or obligation to revise any forward-looking statements, including, without limitation, financial estimates, whether as a result of new information, future events or otherwise.

*Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) is a key indicator used by management to evaluate operating performance. While EBITDA is not intended to replace any presentation included in these consolidated financial statements under generally accepted accounting principles (GAAP) and should not be considered an alternative to operating performance or an alternative to cash flow as a measure of liquidity, BCI believes this measure is useful to investors in assessing its capital expenditures and working capital requirements. This calculation may differ in method of calculation from similarly titled measures used by other companies.

BERLINER COMMUNICATIONS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Amounts in thousands) June 30, 2009 2008 ASSETS CURRENT ASSETS Cash and cash equivalents $1,390 $3,173 Accounts receivable, net of allowance for doubtful accounts of $200 and $830 at June 30, 2009 and 2008, respectively 20,116 31,189 Inventories 1,005 1,012 Income Tax Receivable 2,659 - Deferred tax assets - current 429 536 Prepaid expenses and other current assets 891 762 ------- ------- 26,490 36,672 Property and equipment, net 2,239 2,924 Amortizable intangible assets, net 479 816 Goodwill 2,284 2,084 Deferred tax assets - long-term 2,789 505 Other assets 276 268 ------- ------- Total Assets $34,557 $43,269 ======= ======= LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $4,644 $4,820 Accrued liabilities 3,685 11,919 Accrued income taxes - 1,849 Line of credit 2,967 217 Current portion of long-term debt 777 1,133 Current portion of capital lease obligations 118 118 ------- ------- 12,191 20,056 Long-term debt, net of current portion 18 467 Long-term capital lease obligations, net of current portion 194 305 Other long-term liabilities 105 104 ------- ------- Total liabilities 12,508 20,932 COMMITMENTS STOCKHOLDERS' EQUITY Common stock 1 1 Additional paid-in capital 25,766 22,630 Accumulated deficit (3,718) (294) ------- ------- Total stockholders' equity 22,049 22,337 ------- ------- Total liabilities and stockholders' equity $34,557 $43,269 ======= ======= BERLINER COMMUNICATIONS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except per share data) Year Ended June 30, 2009 2008 Revenue $54,491 $128,372 Costs of revenue 38,786 83,452 ------- ------- Gross profit 15,705 44,920 Selling, general and administrative expenses 20,473 25,703 Depreciation and amortization 1,285 1,190 Gain on sale of fixed assets (8) (11) ------- ------- Income (loss) from operations (6,045) 18,038 Other (income) expense Interest expense 208 1,359 Amortization of deferred financing fees and accretion of debt discount 60 2,031 Interest income (59) (71) Other income (373) (162) ------- ------- Income (loss) before income taxes (5,881) 14,881 Income tax (benefit) expense (2,457) 6,427 ------- ------- Net income (loss) allocable to common shareholders $(3,424) $8,454 ======= ======= Net income (loss) per share: Basic $(0.13) $0.47 ======= ======= Diluted $(0.13) $0.31 ======= ======= Weighted average number of shares outstanding: Basic 26,439 17,918 ======= ======= Diluted 26,439 27,166 ======= =======

Berliner Communications, Inc.

CONTACT: Rich Berliner, Berliner Communications, Inc., +1-201-791-3200,
berlinerr@bcisites.com

Web Site: http://www.bcisites.com/

GEO2 Licenses Patent Portfolio to Corning

WOBURN, Mass., Sept. 28 /PRNewswire/ -- GEO2 Technologies, Inc. and Corning Incorporated today announced a licensing agreement that provides Corning access to GEO2's worldwide patent portfolio. Corning may leverage this technology to develop, manufacture, and sell future applications of its aluminum titanate and cordierite diesel and gasoline emissions control technologies. Terms of the agreement were not disclosed.

About GEO2 Technologies, Inc.

GEO2 Technologies (http://www.geo2tech.com/) is a materials science company that provides a unique and patented Cross-Linked Microstructure (CLM(TM)) for advanced filtration, complex chemical reactions, and medical devices. For emissions control applications, GEO2's microstructure breakthrough is based on its ability to combine high porosity and high strength while maintaining high trapping efficiency and delivering lower back pressure. CLM is offered in multiple materials (oxides, non-oxides and metals) that are extruded using industry standard processes. GEO2 Technologies is headquartered in Woburn, MA.

About Corning Incorporated

Corning Incorporated (http://www.corning.com/) is the world leader in specialty glass and ceramics. Drawing on more than 150 years of materials science and process engineering knowledge, Corning creates and makes keystone components that enable high-technology systems for consumer electronics, mobile emissions control, telecommunications and life sciences. Our products include glass substrates for LCD televisions, computer monitors and laptops; ceramic substrates and filters for mobile emission control systems; optical fiber, cable, hardware & equipment for telecommunications networks; optical biosensors for drug discovery; and other advanced optics and specialty glass solutions for a number of industries including semiconductor, aerospace, defense, astronomy and metrology.

GEO2 Technologies, Inc.

CONTACT: GEO2 Media Relations, Adam Wallen, VP Business Partnerships,
+1-781-569-0559, info@geo2tech.com; Corning Media Relations, Pamela W. Porter,
+1-607-974-9980, porterpw@corning.com, or Lisa A. Burns, +1-607-974-4897,
burnsla@corning.com; Corning Investor Relations, Kenneth C. Sofio,
+1-607-974-7705, sofiokc@corning.com

Web Site: http://www.geo2tech.com/

DreamWorks Animation to Announce Third Quarter 2009 Results and Host Earnings Conference Call

GLENDALE, Calif., Sept. 28 /PRNewswire-FirstCall/ -- DreamWorks Animation SKG, Inc. today announced that the Company's third quarter results will be released on Tuesday, October 27, 2009, after the market close.

DreamWorks Animation will host a conference call and webcast to discuss the results on Tuesday, October 27, 2009, at 4:30 p.m. (ET). Investors can access the call by dialing (800) 230-1074 in the U.S. and (612) 332-0107 internationally and identifying "DreamWorks Animation Earnings" to the operator. The call will also be available via live webcast at http://www.dreamworksanimation.com/.

A replay of the conference call will be available shortly after the call ends on Tuesday, October 27, 2009. To access the replay, dial (800) 475-6701 in the U.S. and (320) 365-3844 internationally and enter 117383 as the conference ID number. Both the earnings release and archived webcast will be available on the Company's website at http://www.dreamworksanimation.com/.

About DreamWorks Animation SKG

DreamWorks Animation is principally devoted to developing and producing computer generated, or CG, animated feature films. With world-class creative talent, a strong and experienced management team and advanced CG filmmaking technology and techniques, DreamWorks Animation makes high quality CG animated films meant for a broad movie-going audience. The Company anticipates releasing its feature films into both conventional and IMAX® theatres worldwide. The Company has theatrically released a total of eighteen animated feature films, including Shrek, Shrek 2, Shark Tale, Madagascar, Over the Hedge, Shrek the Third, Bee Movie, Kung Fu Panda, Madagascar: Escape 2 Africa and Monsters vs. Aliens. All of the Company's feature films are now being produced in stereoscopic 3D technology.

Caution Concerning Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company's plans, prospects, strategies, proposals and our beliefs and expectations concerning performance of our current and future releases and anticipated talent, directors and storyline for our upcoming films and other projects, constitute forward-looking statements. These statements are based on current expectations, estimates, forecasts and projections about the industry in which we operate and management's beliefs and assumptions. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors, and other risks and uncertainties affecting the operation of the business of DreamWorks Animation SKG, Inc. These risks and uncertainties include: audience acceptance of our films, our dependence on the success of a limited number of releases each year, the increasing cost of producing and marketing feature films, piracy of motion pictures, the effect of rapid technological change or alternative forms of entertainment and our need to protect our proprietary technology and enhance or develop new technology. In addition, due to the uncertainties and risks involved in the development and production of animated feature projects, the release dates for the projects described in this document may be delayed. For a further list and description of such risks and uncertainties, see the reports filed by us with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and our most recent quarterly reports on Form 10-Q. DreamWorks Animation is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

DreamWorks Animation

CONTACT: Investor Relations, +1-818-695-3900,
ir@dreamworksanimation.com, or Corporate Communications, +1-818-695-3658,
shannon.olivas@dreamworks.com, both of DreamWorks Animation

Web Site: http://www.dreamworksanimation.com/

Ambitious Partnership Between Vail Resorts, The National Forest Foundation and the USDA Forest Service Aims to Comprehensively Restore Forest Health, Improve Water Quality After Colorado's Largest Forest FireEditor's Note: Interviews will be scheduled after 6:30 p.m. MT at the Denver Museum of Nature and Science (or from the Museum) by contacting akemp@vailresorts.com or janellesmith@fs.fed.us. Photos and video of the Hayman fire are available, as well.

DENVER, Sept. 28 /PRNewswire-FirstCall/ -- Today, United States Secretary of Agriculture Tom Vilsack announced a collaborative conservation partnership - "Treasured Landscapes: The Hayman Restoration Partnership - Working Together for Healthy Forests and Clean Water" - between Vail Resorts, the National Forest Foundation (NFF) and the USDA Forest Service, which will be one of the most comprehensive forest health and watershed public-private partnership post-fire restoration projects in the country. Seven years after Colorado's largest and most devastating wildfire this collaborative work project aims to restore forest health and water quality to this critical ecosystem located approximately 70 miles from Denver.

For 20 days in the summer of 2002, the Hayman fire burned a total of 137,760 acres in the Pike National Forest. In its wake, the fire destroyed 600 structures, obliterated forest vegetation and wildlife habitat for threatened species, damaged recreation sites, trails and roads, resulting in frequent closures of Highway 67. To this day, the fire's aftermath continues to severely impact the water supply for more than 75 percent of Colorado residents.

Set to begin in fall of 2009, The Hayman Restoration Partnership is estimated to be a $4-million effort, with Vail Resorts serving as the private funding catalyst for the work. The Hayman Restoration Partnership is one of several initiated under the National Forest Foundation's Treasured Landscapes forest and watershed restoration campaign.

"Thanks to a significant contribution by Vail Resorts, matched by the US Forest Service, we are about half-way to our goal of fully funding this project," said Bill Possiel, NFF president. The goal is to complete the work by 2012 in time for the 10th anniversary of the Hayman fire.

"The health and prosperity of our country relies on the health of our nation's forests. The threats facing our forests require us to change the way we view and manage America's forestlands, not just for our generation but for future generations," said Agriculture Secretary Tom Vilsack. "The Hayman Restoration Project, spearheaded by the US Forest Service, National Forest Foundation, and Vail Resorts exemplifies our new vision of collaborative conservation, management and restoration of our nation's forests. Through private-public partnerships like this one, we can make our forests more resilient to climate change, protect water resources and improve forest health while creating jobs and generating rural wealth through recreation and tourism."

The total project area for the Hayman Restoration Partnership is over 115,000 thousand acres, with the majority of the work honing in on 45,000 acres of the most severely affected areas in four watersheds that feed into the Upper South Platte River, the main water supply for Denver. Instead of focusing on only one element of restoration, such as planting trees, the Hayman Restoration project will address the entire ecosystem with a multi-faceted and strategic work plan involving restoration and planting of native species in these four watersheds - West Creek, Manitou Park, Lower Trout and Four Mile.

This comprehensive approach extends beyond the on-the-ground work to how the project will be implemented with plans to engage local governments and residents, Vail Resorts employees, conservation organizations and the entire Front Range community. Citizens will have opportunities to help in the restoration work through organized volunteer days. A Local Coordinating Council is being created to help inform the course of the project over the next three years.

The public-private partnership spearheaded by the NFF, the Forest Service and Vail Resorts aims to:

-- Plant more than 200,000 ponderosa pine, Douglas fir and other native trees on 1,700 acres; -- Plant native vegetation, such as willows, dogwood, grasses and sedge, for river restoration on 115 acres, across 13 miles; -- Restore habitat for the endangered Montane skipper butterfly and other threatened species; -- Reduce erosion to improve water quality and positively impact the water supply and storage capacity for millions of Colorado residents; -- Revitalize stream habitats for a gold-medal trout fishery; -- Enhance or create 18 miles of sustainable recreational trails; -- Increase the diversity and resiliency of this critical ecosystem to mitigate future fires, insect infestations and climate change; and -- Create jobs for Colorado youth and engage the community through volunteer opportunities.

Colorado's public lands and natural beauty have long been recognized as defining attributes of the Centennial State, and have served to attract tourists, jobs and economic opportunities making tourism the second largest industry for the state.

"As the largest tourism company in Colorado, Vail Resorts has a unique opportunity and obligation to protect forest health not only for year-round recreational opportunities but also for the environmental and economic vitality of our communities, our state and our country," said Rob Katz, chairman and chief executive officer for Vail Resorts. "The Hayman Restoration Partnership is part of our Company's continuing efforts to take a leadership role in the most pressing environmental issues, which our employees, communities and guests are focused on. There can be no mistaking that "clean water" is absolutely critical to all of our stakeholders."

Katz announced that protecting forest health, including the wildlife, climate change and clean water benefits would be one of the Company's primary environmental efforts in the future and that Vail Resorts would look for additional ways to amplify its actions through public-private partnerships. "We spoke to many leaders in the environmental community and concluded that this was the most pressing issue for our Company to show leadership on. One of the best attributes of the Hayman Restoration Partnership is how our actions will be echoed and amplified, so to speak, as we serve as the catalyst for this project with matching funds from the Forest Service and other entities."

The Hayman Restoration project builds upon Vail Resorts' existing and ongoing partnership with the NFF through the Ski Conservation Fund, which has raised more than $1.5 million to date for conservation and environmental projects in the national forests that surround its resorts.

According to Rick Cables, US Forest Service Rocky Mountain Regional Forester, catastrophic fires like the Hayman wildfire are just one of the threats to Colorado's forests. Climate change, disease and pests like the pine bark beetle infestation also have led to declining forest health. Cables and other forest health experts agree we need a multi-faceted, collaborative strategy to forest stewardship across the state of Colorado and across our country to tackle complex forest health issues.

"These badly burned watersheds need our help now," said Cables. "The Pike National Forest has worked tirelessly, together with many partners, since 2002 to restore these wildlands we all care about; but much more needs to be done."

Without forest vegetation cover, severe erosion in the badly-burned areas of the Upper South Platte River watershed has led to significant sediment deposits in streams and reservoirs, loss of fish and other native species, and impacts to the majority of Denver's water supply.

The health of our forests here in Colorado and elsewhere around the country are vital to ensuring clean water with 87 percent of our country's fresh water supply originating from forests or agricultural watersheds. "The Hayman burn area is the main watershed for the Denver metro area and 75 percent of the state, which makes this project one of our top priorities for the state of Colorado," Cables said. As a matter of fact, Colorado's National Forests provide water to 10 states and 143 counties.

Healthy and sustainable forests are essential to much that is treasured about Colorado, including high quality wildlife habitat, water supplies and recreation, added Tim Sullivan, State Director of the Nature Conservancy Colorado. "We applaud Vail Resorts for taking the lead on this public-private partnership with the National Forest Foundation and Forest Service and feel it will make a meaningful difference in addressing one of Colorado's most pressing conservation issues."

For more information about the project: "Treasured Landscapes: The Hayman Restoration Partnership - Working Together for Healthy Forests and Clean Water," visit http://sites.google.com/site/treasuredlandscapes/.

Vail Resorts, Inc.

CONTACT: Justin DeJong of USDA, +1-202-720-4623,
justin.dejong@oc.usda.gov; or Janelle Smith of USDA Forest Service,
+1-303-275-5359, janellesmith@fs.fed.us; or Amy Kemp of Vail Resorts,
+1-303-404-1863, akemp@vailresorts.com; or Mary Mitsos of National Forest
Foundation, +1-406-542-2805, mmitsos@nationalforests.org

Corporacion GEO's 3rd Quarter 2009 Conference Call / Webcast

MEXICO CITY, Sept. 28 /PRNewswire-FirstCall/ -- Corporacion GEO (BMV: GEOB, Latibex: XGEO, OTC: CVGFY) Mexico's leading low-income housing developer , will hold its third quarter 2009 conference call on Tuesday, October 27, 2009 at 11:00 am U.S. EST (10:00 am Mexico City Time). The earnings press release for the third quarter 2009 will be issued on Monday, October 26, 2009, after market close.

The conference call can be accessed by dialing 888.713.4209 (U.S.) or 617.213.4863 (international) and entering passcode 47373392. We suggest you pre-register for the conference call use the following link:

https://www.theconferencingservice.com/prereg/key.process?key=PLNCCAHQ3

While not mandatory, we recommend you pre-register -- it will provide you immediate and timely entry into the call. You will receive a code that allows you to enter the call directly. Pre-registration only takes a few moments and you may do so at any time, including up to and after call start time. To pre-register, please click the link above. Alternatively, if you would rather be placed into the call by an operator, please call at least 20 minutes prior to call start time.

A replay will be available starting on Tuesday, October 27, 2009 at 2:00 PM US EST, ending at midnight US EST on November 03, 2009. The replay is accessible by dialing 888.286.8010 (U.S.) or 617.801.6888 (international) and entering passcode 93032515.

A live web cast of the conference call and replay will be available at: http://www.corporaciongeo.com/

Corporacion GEO, S.A.B. de C.V. Hans Schroeder Investor Relations Officer +52 555 4805071 hschroeder@casasgeo.com

Corporacion GEO

CONTACT: Hans Schroeder, Investor Relations Officer, of Corporacion GEO,
S.A.B. de C.V., +52 555 4805071, hschroeder@casasgeo.com

Web Site: http://www.corporaciongeo.com/

RadioShack Adds Verizon to Sam's Club(R) Wireless Kiosks

FORT WORTH, Texas, Sept. 28 /PRNewswire-FirstCall/ -- RadioShack Corporation announced today the Company will introduce Verizon Wireless in nearly 450 Sam's Club wireless kiosks that it operates nationwide. Verizon -- the largest U.S. wireless carrier with about 80 million subscribers -- will make its hand-held devices and services available through Sam's Club wireless kiosks operated by RadioShack effective Oct. 1.

"With the addition of Verizon to our kiosk operations, we've established important relationships with all four major wireless carriers in the United States," said Julian C. Day, chairman and CEO of RadioShack Corp. "Our goal is to deliver the best choices and outstanding service to Sam's Club members. As consumers' wireless decisions become more complex, we're prepared to help them sort out the best choice to stay connected on the go."

About RadioShack Corporation

RadioShack Corporation , headquartered in Fort Worth, Texas, is one of the nation's most experienced and trusted consumer electronics specialty retailers, offering innovative products and services from leading brands. Our knowledgeable, helpful sales associates are committed to enhancing the in-store shopping experience by listening to our customers, offering advice, and partnering with them to find the best technology solutions that fit their needs. Operating from convenient and accessible neighborhood and mall locations, the company has approximately 4,450 company-operated stores; almost 1,400 dealer outlets; nearly 600 wireless phone kiosks throughout the U.S.; and approximately 200 company-operated stores in Mexico. For more information on RadioShack Corporation, or to purchase items online, visit http://www.radioshack.com/.

Photo: http://www.newscom.com/cgi-bin/prnh/20000518/DATH047LOGO
http://photoarchive.ap.org/
PRN Photo Desk photodesk@prnewswire.com RadioShack Corporation

CONTACT: Wendy Dominguez, Media Relations of RadioShack Corporation,
+1-817-415-3300, media.relations@radioshack.com

Web Site: http://www.radioshack.com/

Air Products Announces Executive Changes

LEHIGH VALLEY, Pa., Sept. 28 /PRNewswire-FirstCall/ -- Air Products has made the following executive changes, effective October 2009:

Alexander W. Masetti has been appointed vice president, Continuous Improvement, responsible for expanding and institutionalizing Air Products' overall continuous improvement activity, including capabilities such as Six Sigma and Lean. Masetti joined Air Products in 1981 as an engineer in the company's Career Development Program and subsequently held management positions within the Process Gas Division. He has served as vice president for the company's joint venture with San Fu Chemical Company in Taipei, Taiwan; vice president for the company's Daido Air Products Electronics joint venture in Osaka, Japan; and director of Investor Relations. He most recently held the position of vice president, Tonnage Gases North America. Masetti received a B.S. degree in mechanical engineering from Lafayette College in 1981 and an M.B.A. from Lehigh University in 1986.

Wilbur W. Mok has been appointed vice president, North America Tonnage Gases, succeeding Masetti. He will be responsible for leading, directing and growing the North America Tonnage Gases business for existing pipeline, franchise and on-site offerings and business relationships. Mok joined Air Products in 1986 as a financial analyst and subsequently held a variety of domestic and international engineering, commercial and management positions. He has served as president, Air Products China, and most recently held the position of Asia region president. Mok received a B.S. degree in electrical engineering from Northwestern University in 1984 and an M.B.A. in finance from the University of Chicago in 1986.

Michael A. Olivares has been appointed vice president, International. An expansion of his current role as vice president, Latin America/South Africa, he now will have responsibility for the continued growth and profitability of all of Air Products' major international joint ventures and partnerships. Olivares joined Air Products in 1978 as a participant in the company's Career Development Program and held positions in engineering and operations. Olivares has served in a variety of management roles, including general manager for Air Products Puerto Rico and general manager for the company's Bangkok Industrial Gas Ltd. joint venture in Thailand. Olivares received a B.S. degree in mechanical engineering from Drexel University in 1978 and an M.B.A. from Temple University in 1991.

Complete biographies and downloadable photos are available in Air Products' Press Room at http://www.airproducts.com/PressRoom/Biographies/ExecutiveBiographies.htm.

Air Products serves customers in industrial, energy, technology and healthcare markets worldwide with a unique portfolio of atmospheric gases, process and specialty gases, performance materials, and equipment and services. Founded in 1940, Air Products has built leading positions in key growth markets such as semiconductor materials, refinery hydrogen, home healthcare services, natural gas liquefaction, and advanced coatings and adhesives. The company is recognized for its innovative culture, operational excellence and commitment to safety and the environment. Air Products had fiscal 2008 revenues of $10.4 billion, operations in over 40 countries, and 21,000 employees around the globe. For more information, visit http://www.airproducts.com/.

***NOTE: This release may contain forward-looking statements. Actual results could vary materially, due to changes in current expectations.

Air Products

CONTACT: Media, Debbie Bauer, +1-610-481-8061, bauerda@airproducts.com;
Investors, Nelson Squires, +1-610-481-7461, squirenj@airproducts.com

Web Site: http://www.airproducts.com/

Belo Names Bob Simone President and General Manager of KMSB-TV and KTTU-TV in Tucson

DALLAS, Sept. 28 /PRNewswire-FirstCall/ -- Belo Corp. , one of the nation's largest pure-play, publicly-traded television companies, announced today that it has named Robert M. "Bob" Simone president and general manager of its Tucson television stations, KMSB-TV (FOX) and KTTU-TV (MyNetworkTV). A 25-year broadcast television veteran, Simone most recently was with Liberty Media advising the Company on its broadcast industry initiatives.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090928/DA82987)

Peter L. Diaz, Belo's executive vice president/Television Operations, said, "Bob Simone has a proven record in the broadcast industry of building news products and his leadership and management experience will complement Belo's Tucson operations."

Prior to his position at Liberty, Simone spent 20 years at Fox Television Stations, Inc. in a variety of management roles. During his last 11 years with Fox, he was vice president/General Manager of three different Fox owned and operated television stations: KPTV (Portland), KDVR-TV (Denver) and WTFX-TV (Philadelphia). His career also includes senior management positions at WFLD-TV (Chicago) and KSTU-TV (Salt Lake City).

About Belo Corp.

Belo Corp. (BLC) is one of the nation's largest pure-play, publicly-traded television companies, with 2008 annual revenue of $733 million. The Company owns and operates 20 television stations (nine in the top 25 markets) and their associated Web sites. Belo stations, which include affiliations with ABC, CBS, NBC, FOX, CW and MyNetwork TV, reach more than 14 percent of U.S. television households in 15 highly-attractive markets. Belo stations rank first or second in nearly all of their local markets. Additional information is available at http://www.belo.com/ or by contacting Paul Fry, vice president/Investor Relations & Corporate Communications, at 214-977-6835.

Photo: http://www.newscom.com/cgi-bin/prnh/20090928/DA82987
http://photoarchive.ap.org/
AP PhotoExpress Network: PRN#
PRN Photo Desk, photodesk@prnewswire.com Belo Corp.

CONTACT: Paul Fry, vice president/Investor Relations & Corporate
Communications of Belo Corp., +1-214-977-6835

Web Site: http://www.belo.com/

ATK Propulsion and Composite Technologies Key to Successful Delta II LaunchATK Supports NASA's Launch of the Missile Defense Agency's STSS Satellite

MINNEAPOLIS, Sept. 28 /PRNewswire-FirstCall/ -- Alliant Techsystems played a key role in the successful launch of a United Launch Alliance Delta II rocket for NASA from Space Launch Complex 17B at Cape Canaveral Air Force Station, Fla., carrying the Missile Defense Agency's Space Tracking and Surveillance System (STSS) Demonstrators Program satellite.

Nine ATK GEM-40 solid propulsion strap-on boosters provided augmented thrust for the launch. Six of the boosters ignited at lift-off with the first-stage main engine and provided over 824,000 pounds maximum thrust for the launch vehicle. Just over one minute later, the remaining three boosters ignited to provide an additional 427,000 pounds maximum thrust. The spent motors were then jettisoned from the rocket as it continued its ascent.

ATK manufactured the GEM-40 motors at its facility in Magna, Utah, continuing a tradition of flight support for Delta II missions that began in 1990. The composite cases for the GEM-40 boosters were produced at ATK's Clearfield, Utah, facility and are made of graphite epoxy material using an automated filament winding process the company developed and refined through its 50-year heritage in composite manufacturing.

The 10-foot diameter composite payload fairing, encapsulating the payload, was fabricated by ATK's Iuka, Mississippi facility. The fairing was produced using advanced composite hand layup manufacturing, machining, and inspection techniques. This launch marks the 17th ATK built fairing flown on a Delta II mission.

The STSS Demonstrators Program is a midcourse tracking technology demonstrator and is part of an evolving ballistic missile defense system. STSS is capable of tracking objects after boost phase and provides trajectory information to other sensors and interceptors. The mission was launched by NASA for the Missile Defense Agency.

ATK is a premier aerospace and defense company with more than 18,000 employees in 22 states, Puerto Rico and internationally, and revenues of approximately $4.8 billion. News and information can be found on the Internet at http://www.atk.com/.

Media Contact: Investor Contact: George Torres Jeff Huebschen Phone: 801-699-2637 Phone: 952-351-2929 E-mail: george.torres@atk.com E-mail: jeff.huebschen@atk.com

ATK

CONTACT: Media, George Torres, +1-801-699-2637, george.torres@atk.com,
or Investors, Jeff Huebschen, +1-952-351-2929, jeff.huebschen@atk.com, both of
ATK

Web Site: http://www.atk.com/

GeoEye, Inc. Announces Receipt of Required Consents to Its Tender Offer and Consent Solicitation for Its Senior Secured Floating Rate Notes Due 2012

DULLES, Va., Sept. 28 /PRNewswire-FirstCall/ -- GeoEye, Inc. announced today that it has received tenders and consents from the holders of $249.5 million in aggregate principal amount, or approximately 99.8 percent, of its outstanding $250 million Senior Secured Floating Rate Notes due 2012 (the "Notes") as of the expiration of the consent payment deadline, which was September 24, 2009, at 5:00 p.m., New York City time (the "Consent Deadline"). This is pursuant to its previously announced tender offer and consent solicitation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080625/LAW528LOGO)

The consents received exceeded the number required to approve the proposed amendments to the indenture under which the Notes were originally issued. Because the Consent Deadline has passed, Notes tendered and consents given may not be validly withdrawn or revoked whether tendered or given prior to or after the Consent Deadline. The terms of the tender offer and consent solicitation for the Notes are detailed in GeoEye's Offer to Purchase and Consent Solicitation Statement dated September 11, 2009 (the "Offer to Purchase").

Under the terms of the Offer to Purchase, holders who tendered their Notes on or prior to the Consent Deadline will receive $1,070 per $1,000 in principal amount of the Notes validly tendered. Holders who tender their Notes after the Consent Deadline will receive $1,040 per $1,000 in principal amount of the Notes validly tendered. The tender offer is scheduled to expire at midnight, New York City time on October 8, 2009. GeoEye intends to redeem any Notes that remain outstanding after the expiration date of the tender offer on January 22, 2010 and to exercise its rights under the indenture to satisfy and discharge the indenture governing the Notes.

Based on the consents received on the Consent Deadline, GeoEye and the trustee under the indenture have entered into a supplemental indenture that will, once operative, eliminate substantially all of the restrictive covenants and certain event of default provisions and modify certain other provisions of the indenture. The supplemental indenture will become operative upon payment for Notes tendered on or prior to the Consent Deadline and accepted for purchase by GeoEye pursuant to the tender offer, which payment is expected to occur on or about October 9, 2009.

The tender offer is conditioned upon the satisfaction or waiver by GeoEye of certain conditions set forth in the Offer to Purchase. If any of the conditions are not satisfied, GeoEye will not be obligated to accept for purchase, or to pay for, Notes tendered (and corresponding consents) and may delay the acceptance, for payment of, any tendered Notes, in each event, subject to applicable laws, and may terminate, extend or amend the tender offer and may postpone the acceptance for purchase of, and payment for, Notes so tendered.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, purchase or sale would be unlawful. The tender offer is being made solely pursuant to the Offer to Purchase and related transmittal documents.

Requests for documents may be directed to IPREO, the Information Agent, at (877) 746-3583 or (201) 499-3500.

J.P. Morgan Securities Inc. has been engaged to act as Dealer Manager for the tender offer and Solicitation Agent for the consent solicitation. Questions regarding the tender offer and consent solicitation may be directed to J.P. Morgan Securities Inc. at (800) 245-8812.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "anticipates," "believes," "estimates," "expects," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future, including statements relating to the tender offer and any financing related thereto, growth, expected levels of expenditures and statements expressing general optimism about future operating results, are forward-looking statements. Similarly, statements that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements and those presented elsewhere by our management from time to time are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. These risks and uncertainties include, but are not limited to, the satisfaction of conditions to the tender offer, the ability to obtain financing on terms satisfactory to GeoEye and resulting in the receipt by GeoEye of proceeds in an amount sufficient finance the tender offer, and those risks and uncertainties described in "Risk factors" included in our Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2008, which we filed with the Securities and Exchange Commission ("SEC") on April 2, 2009, and our Quarterly Report on Form 10-Q for the period ended March 31, 2009 and June 30, 2009, which we filed with the SEC on May 12, 2009 and Aug. 10, 2009, respectively. A copy of all SEC filings may be obtained from the SEC's EDGAR web site, http://www.sec.gov/, or by contacting: William L. Warren, Senior Vice President, General Counsel and Secretary, at (703) 480-7500.

Photo: http://www.newscom.com/cgi-bin/prnh/20080625/LAW528LOGO
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com GeoEye, Inc.

CONTACT: Investor Relations, Randy Scherago, +1-703-480-7529,
scherago.randy@geoeye.com, or Media, Mark Brender, +1-703-629-5368,
brender.mark@geoeye.com, both of GeoEye

Web Site: http://www.geoeye.com/

Dan Jansen and Pat LaFontaine To Take On the 2009 ING New York City MarathonChampions of the ice team up with the ING Run For Something Better program to encourage children to be physically fit

NEW YORK, Sept. 28 /PRNewswire/ -- Former Olympic speed skater Dan Jansen and National Hockey League (NHL) legend Pat LaFontaine will each trade in their skates for a pair of orange laces and running shoes as they take on their next athletic challenge -- the 2009 ING New York City Marathon.

On Sunday, November 1, 2009, Jansen and LaFontaine will partner with financial services leader ING as they participate in the 40th running of this premiere distance race. The two will be serving as ambassadors for the ING Run For Something Better, a national initiative that promotes youth fitness and provides grants and funding to school-based running programs across the country.

During the marathon, Jansen and LaFontaine will each wear a pair of ING's signature orange shoelaces. Orange laces are given to those who make a charitable donation of $10 or more to the ING Run For Something Better cause. ING's orange laces are available at http://www.orangelaces.com/. The two champions will also raise money for the program through fundraising websites. Fans can support their efforts by visiting http://www.orangelaces.com/nyc.

"As an elite speed skater, it was necessary for me to develop good fitness habits early in life. Starting off on the right foot as a child makes it much easier to lead a healthy lifestyle as an adult," said Jansen. "By participating in the ING Run For Something Better program and running the marathon, I hope to encourage young people across the country to learn about the importance of physical activity and the benefits of setting their own health and fitness goals."

"Not every child is going to become a professional athlete - but they can take the right steps toward leading a healthy life," noted LaFontaine. "My parents and I always focused on proper exercise, training, and nutrition so that I could be as successful as possible. Today, these things are still very important to me. I'm excited to be partnering with ING and supporting the ING Run For Something Better so that other kids can learn these same values."

Dan and Pat's training and involvement in the ING Run For Something Better can be followed on Twitter at http://www.twitter.com/OrangeLaces as well as by visiting a newly launched ING Facebook page (search "ING Run For Something Better" on Facebook).

"We're thrilled to have Dan and Pat join our team as they participate in this year's ING New York City Marathon. Not only are these two men fantastic athletes, but they serve as incredible role models for young people everywhere," said Rhonda Mims, president of the ING Foundation and senior vice president, Office of Corporate Responsibility and Multicultural Affairs. "The ING Run For Something Better program is all about teaching our children the benefits of being healthy and fit, and the dedication it takes to setting and achieving goals in life. The support we get from Dan and Pat will help us continue spreading this positive message."

Childhood obesity has become a serious health concern in the United States. Educating kids about the importance of living an active and healthy life is the cornerstone of the ING Run For Something Better.

Since 2003, over 50,000 children have participated in ING Run For Something Better programs across the country. Children in these programs have reached a milestone of running more than 1.5 million miles. Nationally, ING has committed over $2.5 million to fund grants and school-based running programs through the ING Run For Something Better.

Press inquiries: Joe Loparco ING Americas Office: 860.580.2677 Cell: 860.462.6525 joseph.loparco@us.ing.com About Dan Jansen

Dan Jansen is a former Olympic speed skater best known for winning a gold medal in his final Olympic race in 1994. He was awarded the Amateur Athletic Union's James E. Sullivan Award, presented annually to the outstanding athlete in the U.S. who exhibits the qualities of leadership, character, sportsmanship, and the ideals of amateurism. In honor of his sister, the Dan Jansen Foundation was established, contributing funds for Leukemia research, youth sports, and educational programs. Jansen was inducted into the United States Olympic Hall of Fame in 2004. Today, Jansen is a speed skating commentator for NBC and, from 2005-2007, the skating coach for the NHL's Chicago Blackhawks.

About Pat LaFontaine

Pat LaFontaine is a former center in the National Hockey League (NHL) who played his entire career for all three New York State-based teams: the New York Islanders (1983-1991), Buffalo Sabres (1991-1997), and New York Rangers (1997-98). In 1998, after 15 years in the NHL, LaFontaine retired prematurely as a result of a series of head traumas and concussions suffered through his career. In 2003, he was inducted into the Hockey Hall of Fame and the United States Hockey Hall of Fame. On March 3, 2006, the Buffalo Sabres retired LaFontaine's number 16. He was also inducted into the Sabres Hall of Fame in 2006. Since 2001, the Pat LaFontaine Trophy has been awarded to the winner of the Rangers-Islanders season series. Today, LaFontaine devotes most of his energy today to The Companions in Courage Foundation http://www.cic16.org/ an organization he founded to build interactive game rooms in children's hospitals throughout North America.

About ING

ING is a global financial institution of Dutch origin offering banking, investments, life insurance and retirement services to over 85 million private, corporate and institutional clients in over 40 countries. With a diverse workforce of more than 110,000 people, ING is dedicated to setting the standard in helping our clients manage their financial future. In the U.S., the ING family of companies offers a comprehensive array of financial services to retail and institutional clients, which includes life insurance, retirement plans, mutual funds, managed accounts, alternative investments, direct banking, institutional investment management, annuities, employee benefits, financial planning, and reinsurance. ING holds top-tier rankings in key U.S. markets and serves approximately 30 million customers across the nation. For more information, visit http://www.ing.com/US.

About the ING Run For Something Better

The ING Run For Something Better is a fundraising campaign that supports community and school-based youth running programs. Linked to ING's long-distance race sponsorships, the program was created to introduce kids to the benefits of sport, a habit of physical fitness, and a healthy lifestyle that prevents conditions such as childhood obesity. In today's world of poor nutrition and less-active lifestyles -- which may contribute to childhood obesity -- ING is using its position as a sponsor of marathons as a platform for helping kids get fit through free, school-based running programs. Nationally, ING has committed over $2.5 million to fund grants and school-based running programs through ING Run For Something Better. Since 2006, over a half a million dollars has been raised by individual donors through the orange laces program. ING has also created a special charitable fund to encourage others to support the cause by making their own contribution. When someone donates $10 or more to the ING Run For Something Better, ING will recognize their contribution by giving them a special pair of orange shoelaces to wear showing that they are "tied" to supporting kids' fitness. 100% of the proceeds from the sale of orange laces go to the ING Run For Something Better fitness programs. For more information about the orange laces, go to http://www.orangelaces.com/.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Rhonda Mims

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=86660

ING Americas

CONTACT: Joe Loparco of ING Americas, Office: +1-860-580-2677, Cell:
+1-860-462-6525, joseph.loparco@us.ing.com

Web Site: http://www.ing.com/us

Webcast Alert: Banco Compartamos Third Quarter Conference Call Webcast

MEXICO CITY, Sept. 28 /PRNewswire-FirstCall/ -- Banco Compartamos, S.A.B. de C.V. (BMV: COMPART) announces the following webcast:

What: Banco Compartamos Third Quarter Conference Call When: Wednesday, October 21, 2009 at 10:00 A.M. Eastern Where: http://www.videonewswire.com/event.asp?id=62404

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Maria Barona, mbarona@i-advize.com, (212) 406-3691

If you are unable to participate during the live webcast, the call will be archived at http://www.videonewswire.com/event.asp?id=62404.

Banco Compartamos, S.A.B. de C.V.

CONTACT: Maria Barona, i-advize, +1-212-406-3691, mbarona@i-advize.com,
for Banco Compartamos

Web site: http://www.videonewswire.com/event.asp?id=62404

EESO Addresses SEC Complaint

FORT WAYNE, IN, Sept. 28 /PRNewswire-FirstCall/ -- On September 24, 2009, Enzyme Environmental Solutions (PINKSHEETS : EESO) and its' CEO Jared Hochstedler were named in a complaint filed by the U.S. Security Exchange Commission. Hochstedler states, "We are cooperating with the SEC and are currently evaluating our options for response. Until further notice, we will not issue any additional shares of stock."

In the meantime, EESO is still a viable, active company and will continue to operate in all levels of research, sales, production and delivery. President Mark Murphy will continue to lead the staff and team of independent contractors as they strive to establish the company as a significant player in the green cleaning and odor remediation markets.

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Enzyme Environmental Solutions

CONTACT: Newbauer Media Relations, Email: mark@enzymeconsultants.com

Transportation Security Administration Awards CSC Contract for Information Technology Infrastructure Services

FALLS CHURCH, Va., Sept. 28 /PRNewswire-FirstCall/ -- CSC announced today that the Transportation Security Administration (TSA) awarded the company a task order to support the Information Technology Infrastructure Program (ITIP). The task order, which falls under the Department of Homeland Security (DHS) Enterprise Acquisition Gateway for Leading Edge Solutions (EAGLE) contract, has a one-year base period and four one-year options with an estimated five-year contract value of $493 million.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090422/CSCLOGO)

Under the terms of the task order agreement, CSC will provide IT infrastructure services in support of the TSA. The ITIP services will support each of the TSA Office of Information Technology divisions for IT security, solutions delivery, business activities and operational effectiveness throughout the nation, including all U.S. airports.

"CSC recognizes the critical role the Transportation Security Administration plays in protecting the nation's transportation systems," said Aaron Fuller, president of CSC's North American Public Sector Enforcement, Security and Intelligence Group. "We look forward to providing world-class information technology services that will improve the performance and reliability of the agency's infrastructure."

The objective of the DHS EAGLE program is to provide an acquisition vehicle for a full range of IT services, technical and management expertise and solution-related enabling products.

About CSC

CSC is a global leader in providing technology-enabled solutions and services through three primary lines of business. These include Business Solutions and Services, the Managed Services Sector and the North American Public Sector. CSC's advanced capabilities include systems design and integration, information technology and business process outsourcing, applications software development, Web and application hosting, mission support and management consulting. Headquartered in Falls Church, Va., CSC has approximately 92,000 employees and reported revenue of $16.2 billion for the 12 months ended July 3, 2009. For more information, visit the company's Web site at http://www.csc.com/.

Photo: http://www.newscom.com/cgi-bin/prnh/20090422/CSCLOGO
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com CSC

CONTACT: Michelle Herd, Senior Manager, Communications, North American
Public Sector, +1-703-205-6186, mherd@csc.com, or Chris Grandis, Media
Relations Director, Corporate, +1-703-641-2316, cgrandis@csc.com, or Bryan
Brady, Vice President, Investor Relations, Corporate, +1-703-641-3000,
investorrelations@csc.com, all of CSC

Web Site: http://www.csc.com/

page 1 page 2 page 3 page 4 page 5 page 6 page 7 page 8 page 9

News archive of November 2009
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

News Archives of September 2009
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

News Archives other dates
2009: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2008: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2007: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2006: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Datasheet begin: 0 1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Distributors inventory: 0 1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z